Lamotrigine in the Immediate Treatment of Outpatients With Depersonalization Disorder Without Psychiatric Comorbidity

Aliyev, Nadir A.; Aliyev, Zafar N.

doi:10.1097/jcp.0b013e31820428e1

Cited by 23 publications

(21 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PRISMA guidelines were also followed to ensure that the methodology and reporting were comprehensive. Data items 11 Aliyev and Aliyev 2011 ;Sierra et al 2003 ;Simeon et al 2004 and Schoenberg et al 2012 Participants All participants diagnosed with depersonalisation disorder according to the criteria of the Diagnostic and Statistical Manual (DSM-III-R or DSM-IV), or the International Classification of Diseases (ICD-9 or ICD-10) irrespective of age, in- or outpatient status, or presence of comorbidity. Interventions All medication agents and non-pharmacological interventions (e.g.…”

Section: Methodsmentioning

confidence: 99%

“… Results Study selection 17 Records identified through database searching: n = 1296; Records excluded: n = 237, Reason: Duplicates; Title screening: n = 1059; Records excluded: n = 341, Reason: Not Depersonalisation/derealisation; Abstract screening: n = 718; Records excluded: n = 689, Reason: Not treatment articles or no outcome provided; Full-text articles assessed for eligibility: n = 29; Full-text articles excluded: n = 25, Reasons: Retrospective studies and open trials; Studies included in qualitative synthesis: n = 4. Study characteristics 18 Medication ● Aiyev 2011 : Azerbaijani outpatients, single center, lamotrigine (25–300 mg/day), placebo comparison, 12 weeks, 80 randomised, mean age 37.7; 0% female, diagnostics: CDS. ● Sierra et al 2003 : UK outpatients, single center, Lamotrigine (25–250 mg/day), placebo comparison, 12 weeks, 14 randomised, mean age 35.2, diagnostics: DSM-IV, PSE, CDS.…”

Section: Methodsmentioning

confidence: 99%

“… ● Sierra et al 2003 : UK outpatients, single center, Lamotrigine (25–250 mg/day), placebo comparison, 12 weeks, 14 randomised, mean age 35.2, diagnostics: DSM-IV, PSE, CDS. ● Simeon 2004 : USA outpatients, single center, Fluoxetine (10–60 mg/day Eli Lilly); placebo comparison, 10 weeks, 54 randomised, mean age 36, 39% female, diagnostics: SCID-D. Psychotherapy ● Schoenberg et al 2012 : UK outpatients, single center, electro-dermal biofeedback, sham electro-dermal biofeedback, 4 weeks (8 sessions), 32 randomised, mean age 35, 25% female, diagnostics: SCID-D. Risk of bias within studies 19 Medication ● Aliyev and Aliyev 2011 : random sequence generation - low; allocation concealment - low; blinding (performance bias and detection bias) - low; blinding of outcome assessment - low; incomplete outcome data - low; selective outcome reporting - unclear. ● Sierra et al 2003 : random sequence generation - low; allocation concealment - low; blinding (performance bias and detection bias) - unclear; blinding of outcome assessment - low; incomplete outcome data - low; selective outcome reporting - unclear.…”

Section: Methodsmentioning

confidence: 99%

“… ● Sierra et al 2003 : A cross-over study among nine individuals suffering from DPRD comparing the lamotrigine with a placebo revealed following a 2-week washout that lamotrigine had no significant advantage over placebo when administered singularly for DPRD. ● Aliyev and Aliyev 2011 : 12 weeks of lamotrigine therapy resulted in a statistically significant difference in improvement in a lamotrigine group compared with that in the placebo group. Psychotherapy ● Schoenberg 2012 : While electro-dermal biofeedback did not help DPRD participants increase skin conductance response, real-time biofeedback resulted in lower state (but not trait) scores on the CDS.…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Evidence-based treatment for Depersonalisation-derealisation Disorder (DPRD)

2013

View full text Add to dashboard Cite

BackgroundDepersonalisation-derealisation disorder (DPRD) is a distressing and impairing condition with a pathophysiology that is not well understood. Nevertheless, given the growing interest in its pathogenesis, and the publication of a number of treatment trials, a systematic review of randomised controlled pharmacotherapy and psychotherapy trials is timely.MethodsA systematic search of articles on DPRD published from January 1980 to August 2012, using Cochrane methods, was conducted. All randomised controlled trials (RCTs) of pharmacotherapy, psychotherapy, somatic interventions and a blend of these modalities for the treatment of depersonalisation disorder were included in the review. Searches were carried out on multiple databases. The bibliographies of all identified trials were checked for additional studies and authors were contacted for published trials. No unpublished trials were found and no restrictions were placed on language and setting. Data extraction sheets were further designed to enter specified data from each trial and risk of bias information was identified. PRISMA guidelines were also followed to ensure that our methodology and reporting were comprehensive. Of the unique 1296 papers that were retrieved, four studies met the inclusion criteria and were reviewed.ResultsFour RCTs (all within the duration of 12 weeks or less) met study criteria and were included (180 participants; age range 18–65 years). The four RCTs included two lamotrigine studies, one fluoxetine study and one biofeedback study. Evidence for the treatment efficacy of lamotrigine was found in one study (Cambridge Dissociation Scale, CDC: p < 0.001) with no evidence of effect for lamotrigine in the second study (CDS: p = 0.61 or Present State Examination: p = 0.17). Fluoxetine and biofeedback were not more efficacious than the control condition, although there was a trend for fluoxetine to demonstrate greater efficacy in those with comorbid anxiety disorder. The four studies had 'low' or 'unclear' risk of bias.ConclusionThe limited data from randomised controlled trials on the pharmacotherapy and psychotherapy of DPRD demonstrates inconsistent evidence for the efficacy of lamotrigine, and no efficacy for other interventions. Additional research on this disorder is needed.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Evidence-based treatment for Depersonalisation-derealisation Disorder (DPRD)

2013

View full text Add to dashboard Cite

show abstract

“…2 Despite its prevalence and clinical significance, depersonalization disorder is poorly recognized and researched. 3,5,6 In addition, 1 retrospective study suggests the beneficial effects of the use of lamotrigine plus antidepressant medication. In addition, to date, there is no evidently effective treatment for depersonalization disorder.…”

mentioning

confidence: 99%

Aripiprazole in Depersonalization Disorder Comorbid With Major Depression and Obsessive-Compulsive Disorder

Uğuz

Sahingoz

2014

Clinical Neuropharmacology

View full text Add to dashboard Cite

Depersonalization is a frequent symptom in depression and obsessive-compulsive disorder (OCD), but sometimes, it may be severe and concurrently diagnosed as a disorder. The treatment of depersonalization disorder both alone and comorbid with other psychiatric disorders is as yet unclear. This report presents the successful treatment with aripiprazole of concurrent depersonalization disorder in 3 patients with depression or OCD. The psychiatric disorders were diagnosed through structured clinical interviews. Assessments were by means of Yale-Brown Obsessive-Compulsive Scale, the Clinical Global Impression-Improvement Scale, and the 17-item Hamilton Rating Scale for Depression. Aripiprazole may be a beneficial psychotropic drug in the treatment of depersonalization disorder comorbid with OCD or depression, which is an important problem in clinical practice.

show abstract